ResMed Inc
(ASX:RMD) has slightly improved its net profit and revenue over the 2015 financial year.
The US based sleep disorder company’s annual net profit grew 2 per cent to $US353 million while revenue rose 8 per cent to $US1.7 billion.
CEO Mick Farrell says the company achieved a solid return to growth in its mask business, continued an active share repurchase program and lifted its dividend.
Looking ahead ResMed is aiming to change 20 million lives by 2020 with innovative products and solutions.
The company is targeting to improve patient outcomes, reduce the impact of chronic disease and lower healthcare costs.
